Info: Read More
  • 中药标准品生产商,产品定制服务
  • Science | Nature | Cell | View More

    肾上腺素

    Adrenaline

    肾上腺素
    产品编号 CFN90032
    CAS编号 51-43-4
    分子式 = 分子量 C9H13NO3 = 183.2
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Alkaloids
    植物来源 From the adrenal gland of Pig.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    肾上腺素 CFN90032 51-43-4 10mg QQ客服:1413575084
    肾上腺素 CFN90032 51-43-4 20mg QQ客服:1413575084
    肾上腺素 CFN90032 51-43-4 50mg QQ客服:1413575084
    肾上腺素 CFN90032 51-43-4 100mg QQ客服:1413575084
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Centralised Purchases Unit (CPU), B.I.T.S (India)
  • Anna University (India)
  • University of Minnesota (USA)
  • University of Stirling (United Kingdom)
  • Monash University (Australia)
  • China Medical University (Taiwan)
  • Heidelberg University (Germany)
  • University of Padjajaran (Indonesia)
  • Macau University of Science and Technology (China)
  • University of Indonesia (Indonesia)
  • Chiang Mai University (Thailand)
  • University of Auckland (New Zealand)
  • Charles Sturt University (Denmark)
  • Universidad Miguel Hernández (Spain)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Phytomedicine.2015, 22(14):1262-8
  • Phytomedicine.2015, 22(4):498-503
  • J. of The Korean Society of Food Culture2017, 144-149
  • J Ethnopharmacol.2017, 197:157-164
  • Molecules.2017, 22(12)
  • Phytochemistry Letters2017, 449-455
  • Korean J. of Horticultural Sci. & Tech. 2017, 793-804
  • Front Cell Infect Microbiol.2018, 8:292
  • Front Immunol.2018, 9:2091
  • Cell Death Dis.2019, 10(12):882
  • Biomed Pharmacother.2019, 111:262-269
  • Nutr Metab (Lond).2019, 16:31
  • Exp Biol Med (Maywood).2019, 244(16):1463-1474
  • Phytomedicine.2019, 58:152893
  • Int Immunopharmacol.2019, 71:22-31
  • Sci Rep.2019, 9(1):6429
  • Plant Foods Hum Nutr.2020, 10.1007
  • Dent Mater J.2020, 39(4):690-695
  • Nutr Res Pract.2020, 14(3):203-217.
  • Plant Archives2020, 2(1),2929-2934
  • Evid Based Complement Alternat Med.2020, 2020:1970349.
  • Food Chem.2020, 332:127412
  • Molecules2021, 26(1),230
  • ...
  • 生物活性
    Description: L-Epinephrine is a hormone secreted by the medulla of the adrenal glands. L-Epinephrine is an α-adrenergic and β-adrenergic receptor agonist.Epinephrine-MC RDSTs facilitated a twofold increase in epinephrine absorption and a 50% reduction in the sublingual dose, this novel sublingual tablet formulation is potentially useful for the first-aid treatment of anaphylaxis in community settings. Pre-hospital administration of Adrenaline by emergency medical services improves the long term outcome in patients with out of hospital cardiac arrest, although the absolute increase of neurologically intact survival was minimal.
    Targets: Adrenergic Receptor | COX | PGE
    In vitro:
    BMJ. 2013 Dec 10;347:f6829.
    Evaluation of pre-hospital administration of adrenaline (epinephrine) by emergency medical services for patients with out of hospital cardiac arrest in Japan: controlled propensity matched retrospective cohort study.[Pubmed: 24326886]
    To evaluate the effectiveness of pre-hospital Adrenaline (epinephrine) administered by emergency medical services to patients with out of hospital cardiac arrest. DESIGN: Controlled propensity matched retrospective cohort study, in which pairs of patients with or without (control) Adrenaline were created with a sequential risk set matching based on time dependent propensity score. SETTING: Japan's nationwide registry database of patients with out of hospital cardiac arrest registered between January 2007 and December 2010.
    METHODS AND RESULTS:
    Among patients aged 15-94 with out of hospital cardiac arrest witnessed by a bystander, we created 1990 pairs of patients with and without Adrenaline with an initial rhythm of ventricular fibrillation or pulseless ventricular tachycardia (VF/VT) and 9058 pairs among those with non-VF/VT. Overall and neurologically intact survival at one month or at discharge, whichever was earlier. RESULTS: After propensity matching, pre-hospital administration of Adrenaline by emergency medical services was associated with a higher proportion of overall survival (17.0% v 13.4%; unadjusted odds ratio 1.34, 95% confidence interval 1.12 to 1.60) but not with neurologically intact survival (6.6% v 6.6%; 1.01, 0.78 to 1.30) among those with VF/VT; and higher proportions of overall survival (4.0% v 2.4%; odds ratio 1.72, 1.45 to 2.04) and neurologically intact survival (0.7% v 0.4%; 1.57, 1.04 to 2.37) among those with non-VF/VT.
    CONCLUSIONS:
    Pre-hospital administration of Adrenaline by emergency medical services improves the long term outcome in patients with out of hospital cardiac arrest, although the absolute increase of neurologically intact survival was minimal.
    Resuscitation. 2014 Mar;85(3):350-8.
    Adrenaline (epinephrine) dosing period and survival after in-hospital cardiac arrest: a retrospective review of prospectively collected data.[Pubmed: 24252225]
    BACKGROUND AND AIM: Expert guidelines for treatment of cardiac arrest recommend administration of adrenaline (epinephrine) every three to five minutes. However, the effects of different dosing periods of adrenaline remain unclear. We sought to evaluate the association between adrenaline average dosing period and survival to hospital discharge in adults with an in-hospital cardiac arrest (IHCA). METHODS: We performed a retrospective review of prospectively collected data on 20,909 IHCA events from 505 hospitals participating in the Get With The Guidelines-Resuscitation (GWTG-R) quality improvement registry. adrenaline average dosing period was defined as the time between the first adrenaline dose and the resuscitation endpoint, divided by the total number of adrenaline doses received subsequent to the first adrenaline dose. Associations with survival to hospital discharge were assessed by using generalized estimating equations to construct multivariable logistic regression models. RESULTS: Compared to a referent adrenaline average dosing period of 4 to <5 min per dose, survival to hospital discharge was significantly higher in patients with the following adrenaline average dosing periods: for 6 to <7 min/dose, adjusted odds ratio [OR], 1.41 (95%CI: 1.12, 1.78); for 7 to <8 min/dose, adjusted OR, 1.30 (95%CI: 1.02, 1.65); for 8 to <9 min/dose, adjusted OR, 1.79 (95%CI: 1.38, 2.32); for 9 to <10 min/dose, adjusted OR, 2.17 (95%CI: 1.62, 2.92). This pattern was consistent for both shockable and non-shockable cardiac arrest rhythms. CONCLUSION: Less frequent average adrenaline dosing than recommended by consensus guidelines was associated with improved survival of in-hospital cardiac arrest.
    In vivo:
    J Pharm Pharmacol. 2015 Jan;67(1):20-5.
    Adrenaline (epinephrine) microcrystal sublingual tablet formulation: enhanced absorption in a preclinical model.[Pubmed: 25256073]
    For anaphylaxis treatment in community settings, Adrenaline (epinephrine) administration using an auto-injector in the thigh is universally recommended. Despite this, many people at risk of anaphylaxis in community settings do not carry their prescribed auto-injectors consistently and hesitate to use them when anaphylaxis occurs.The objective of this research was to study the effect of a substantial reduction in Adrenaline (Epi) particle size to a few micrometres (Epi microcrystals (Epi-MC)) on enhancing Adrenaline dissolution and increasing the rate and extent of sublingual absorption from a previously developed rapidly disintegrating sublingual tablet (RDST) formulation in a validated preclinical model.
    METHODS AND RESULTS:
    The in-vivo absorption of Epi-MC 20 mg RDSTs and Epi 40 mg RDSTs was evaluated in rabbits. Epi 0.3 mg intramuscular (IM) injection in the thigh and placebo RDSTs were used as positive and negative controls, respectively. Epimean (standard deviation) area under the plasma concentration vs time curves up to 60 min and Cmax from Epi-MC 20 mg and Epi 40 mg RDSTs did not differ significantly (P > 0.05) from Epi 0.3 mg IM injection. After Adrenaline, regardless of route of administration, pharmacokinetic parameters were significantly higher (P < 0.05) than after placebo RDSTs administration (reflecting endogenous Adrenaline levels).
    CONCLUSIONS:
    Epi-MC RDSTs facilitated a twofold increase in Epi absorption and a 50% reduction in the sublingual dose. This novel sublingual tablet formulation is potentially useful for the first-aid treatment of anaphylaxis in community settings.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 5.4585 mL 27.2926 mL 54.5852 mL 109.1703 mL 136.4629 mL
    5 mM 1.0917 mL 5.4585 mL 10.917 mL 21.8341 mL 27.2926 mL
    10 mM 0.5459 mL 2.7293 mL 5.4585 mL 10.917 mL 13.6463 mL
    50 mM 0.1092 mL 0.5459 mL 1.0917 mL 2.1834 mL 2.7293 mL
    100 mM 0.0546 mL 0.2729 mL 0.5459 mL 1.0917 mL 1.3646 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    α-乙酰氨基肉桂酸; 2-(Acetylamino)-3-phenyl-2-propenoic acid CFN98187 5469-45-4 C11H11NO3 = 205.21 100mg QQ客服:1413575084
    辛弗林; Synephrine CFN99551 94-07-5 C9H13NO2 = 167.21 20mg QQ客服:2159513211
    大麦芽碱; Hordenine CFN99901 539-15-1 C10H15NO = 165.24 20mg QQ客服:3257982914
    奴夫卡因; Procaine CFN94479 59-46-1 C13H20N2O2 = 236.31 20mg QQ客服:2056216494
    酪胺; Tyramine CFN96470 51-67-2 C8H11NO = 137.18 20mg QQ客服:2056216494
    2-(N,N-二甲氨基)对苯甲酮; 2-(N,N-Dimethylamino)acetophenone CFN00015 3319-03-7 C10H13NO = 163.22 5mg QQ客服:3257982914
    2-Amino-3-(3-bromo-5-chloro-4-hydroxyphenyl)propanoic acid; 2-Amino-3-(3-bromo-5-chloro-4-hydroxyphenyl)propanoic acid CFN00016 N/A C9H9BrClNO3 = 294.53 5mg QQ客服:2056216494
    2-氨基-1-苯基乙基苯甲酸酯; Trichophydine CFN00055 67031-54-3 C15H15NO2 = 241.29 5mg QQ客服:2932563308
    p-3-甲氨基正丙基苯酚; p-3-Methylamino propyl phenol CFN00078 32180-92-0 C10H15NO = 165.23 5mg QQ客服:1457312923
    盐酸多巴胺; Dopamine hydrochloride CFN90036 62-31-7 C8H11NO2 = 153.18 20mg QQ客服:1413575084

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ1: 2056216494 ; QQ2: 3257982914
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产